Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 9;322(2):166-167.
doi: 10.1001/jama.2019.6581.

Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans

Tami L Mark  1 , William Parish  2 , Gary A Zarkin  2
Affiliations

Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans

Tami L Mark et al. JAMA. .

Abstract

This study describes changes in the proportion of Medicare Part D plans requiring prior authorization for buprenorphine products before and after a 2017 FDA rquirement that the drug’s label emphasize the importance of drug treatment of opioid use disorder.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All 3 authors are salaried employees of RTI International. Their work is funded through federal and state agency contracts and grants.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Han BH, Sherman SE, Palamar JJ. Prescription opioid misuse among middle-aged and older adults in the United States, 2015-2016. Prev Med. 2019;121:94-98. doi:10.1016/j.ypmed.2019.02.018 - DOI - PMC - PubMed
    1. Hartung DM, Johnston K, Geddes J, Leichtling G, Priest KC, Korthuis PT. Buprenorphine coverage in the Medicare Part D program for 2007 to 2018. JAMA. 2019;321(6):607-609. doi:10.1001/jama.2018.20391 - DOI - PMC - PubMed
    1. Park Y, Raza S, George A, Agrawal R, Ko J. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. J Manag Care Spec Pharm. 2017;23(8):893-901. - PMC - PubMed
    1. US Food and Drug Administration Statement from FDA Commissioner Scott Gottlieb, MD, on the agency’s continued efforts to promote the safe adoption of medication-assisted treatment for opioid addiction. https://www.fda.gov/news-events/press-announcements/statement-fda-commis.... Accessed April 4, 2019.
    1. Centers for Medicare & Medicaid Services Announcement of calendar year 2019 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Dow.... Accessed April 4, 2019.